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1. Introduction 18 
Titanate nanotubes (TNT) are newly explored and promising nanomaterials for a wide 19 
range of medical applications. Among others, they show aptness to be used as 20 
radiosensitizer agents in radiotherapy [1], biocompatible biosensors [2] or cell viability 21 
and proliferation enhancing materials for orthopaedic and periodontal use [3, 4]. 22 
Besides, TNTs proved their capacity of being loaded with various active pharmaceutical 23 
ingredients (API) and therefore came into focus of pharmaceutical research as carrier 24 
materials [5, 6].  25 
Based on the experimental results, drug loaded TNTs may provide development in 26 
many issues of pharmaceutical sciences. On the one hand, TNTs carrying nano-sized 27 
APIs may overcome fundamental difficulties related to the formulation and 28 
manufacturing of nanocrystalline active substances, which may show an unavoidable 29 
tendency to autoaggregation, thereby worsening their physicochemical properties and 30 
setting a limit to their commercialization. On the other hand, TNTs show an ability to 31 
achieve targeted drug delivery and controlled drug release, offering to put new and 32 
modern medical therapies into practice [7, 8]. From this aspect, the outstanding 33 
mechanical properties of TNTs may help to overcome formulation problems of other 34 
nanocarriers such as dendrimers, micelles, liposomes, etc., which are available on the 35 
market, but their large-scale manufacturing, stabilization as well as their processing into 36 
solid dosage forms require great efforts [9]. The present study aims to investigate the 37 
suitability of hydrothermally synthesized TNTs for the improvement of the processing 38 
of nano-sized APIs into solid dosage forms with direct compression method. 39 
The structure of a tablet is influenced by many parameters, such as the physicochemical 40 
properties of the compressed materials, the type of the tablet press, the applied 41 
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compression force, etc. [10]. When focusing on the materials, the understanding of the 42 
behaviour of the compressed substances is essential for the commercial scale 43 
manufacturing of tablets. In order to reveal the tablettability of hydrothermally 44 
synthesized TNTs and estimate their influence on the rheological properties of APIs, 45 
which is a completely new field in pharmaceutical research, a competitive study was 46 
performed involving four APIs and their 1:1 ratio composites formed with TNTs. By 47 
using an instrumented tableting machine, the monitoring of the compression cycle is 48 
feasible and with the help of statistical models flowability, particle rearrangement and 49 
compressibility of the compressed materials are possible to be determined [11, 12]. In 50 
the present study the Kawakita-Lüdde and Walker compression models were applied to 51 
estimate the compressibility characteristics and the deformation mechanism of the API 52 
and API-TNT composite containing powder mixtures. The widely used Kawakita-53 
Lüdde model [13] describes the volume reduction of the powder at a given compression 54 
pressure as a function of the pressure and therefore makes the analysis of particle 55 
rearrangement and compactibility possible. However, it does not give much information 56 
about the deformation mechanism of the powders, thus it is necessary to complement 57 
the analysis with another model. The Walker model [14], which expresses the volume 58 
reduction corresponding to a one-decade change in pressure, allows the characterisation 59 
of powder compressibility and therefore completes the Kawakita equation perfectly. 60 
Although the calculated parameters can serve to predict the post-compressional 61 
properties, tablets were investigated thoroughly in order to better understand the effects 62 
of TNT composite formation on tablet properties. 63 
 64 
2. Materials and methods 65 
2.1. Materials 66 
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Diltiazem hydrochloride (DiltHCl), diclofenac sodium (DicNa), atenolol (ATN) and 67 
hydrochlorothiazide (HCT) were kindly supported by Sanofi-Aventis PLC, Egis 68 
Pharmaceuticals PLC, TEVA Pharmaceuticals PLC and Gedeon Richter PLC, 69 
respectively. The following 1:1 ratio of active pharmaceutical ingredient (API)-70 
hydrothermally synthesized titanate nanotube (TNT) composites were produced by the 71 
University of Szeged, Department of Applied and Environmental Chemistry: diltiazem 72 
hydrochloride-TNT (DiltTi), diclofenac sodium-TNT (DicTi), atenolol-TNT (ATNTi), 73 
hydrochlorothiazide-TNT (HCTTi). Excipients for tableting were Avicel PH 112 (FMC 74 
Biopolymer Inc., USA), Tablettose 70 (Meggle Pharma GbbH, Germany), talc and 75 
magnesium stearate. 76 
 77 
2.2. Preformulation study 78 
The flowing properties of the APIs and the API-TNT composites were examined by a 79 
software-controlled PTG-1 (Pharma Test Apparatebau AG, Germany) powder 80 
rheological tester. A stainless-steel funnel with a 10-mm-diameter outlet nozzle was 81 
filled with 100 ml of bulk powder and the powder flow was detected by IR sensors. The 82 
equipment measured the flow time and calculated the angle of repose of the powder 83 
heap. 84 
Densification studies were performed for the APIs and the composites with a STAV 85 
2003 Stampfvolumeter (Engelsmann AG., Germany). 250 ml of powder was put into a 86 
graduated cylinder taking care that the powder does not pack. This volume served to 87 
calculate the bulk density. The powder in the cylinder was mechanically tapped by the 88 
apparatus at a speed of 1/sec until no further decrease in volume could be observed or 89 
until tap number 1250 was reached. The volume of the densified powder was used to 90 
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calculate the tap density. The Hausner Ratio (Eq. (1)) and Compressibility Index (Eq. 91 
(2)) values of the samples were determined as follows: 92 
Hausner Ratio =  (1) 93 
Compressibility Index = [ )] * 100(%) (2) 94 
where  is the tap density and  is the bulk density of the powder in g/cm
3
.The 95 
evaluation of the results was based on the USP scale of flowability [15]. 96 
In order to determine the porosity of the APIs and the composites, the pycnometric 97 
volume of the powders was measured with a Quantachrome Helium 98 
Multipycnometer (Quantachrome GmbH, Germany). The porosity was calculated 99 
by applying Eq. (3): 100 
ε = [1 - ( )] * 100 (3) 101 
where ε is the porosity (%),  is the bulk density and  is the pycnometric 102 
density of the powder in g/cm
3
. 103 
 104 
2.3. Tableting 105 
Tablets containing APIs and API-TNT composites were formulated. The compositions 106 
of the tablets displayed in Table 1. were designed for constant tablet weight (300 107 
mg) and quantity of API (50 mg) in order to respect the therapeutic goals and be 108 
able to compare the API and API-TNT tablets according to the pharmaceutical 109 
requirements.  110 
The powders were mixed with a Turbula (Willy A. Bachofen Maschienenfabrik, 111 
Switzerland) mixer at 50 rpm for 8 minutes without magnesium-stearate and for 2 112 
 
 
6 
 
minutes more with it. The weight of the tablets was designed to be about 300 mg. The 113 
tablets were produced by the direct compression method with a Korsch EK0 (E. Korsch 114 
Maschienenfabrik GmbH, Germany) eccentric tablet press, instrumented with strain 115 
gauges and a displacement transducer. 10-mm-diameter flat punches were applied with 116 
a compression force of 5.0, 7.5, 10.0, 12.5 and 15.0 kN for all the compositions.  117 
 118 
2.4. Compaction properties 119 
The compaction properties of the powder mixtures (Table 1.) were estimated according 120 
to the out-of-the-die method using the Kawakita and Walker models.  121 
The Kawakita equation (Eq. (4)) was used to study the particle rearrangement of the 122 
powder mixtures during the compression: 123 
P/C = P/a + 1/ab (4) 124 
where P is the applied pressure in MPa, C is the degree of the volume reduction and a 125 
and b are constants. The degree of volume reduction is expressed by Eq. (5): 126 
C = (V0-V)/V0 (5) 127 
where V0 is the initial volume of the powder bed and V is the volume of the powder bed 128 
at the applied pressure in mm
3
. 129 
Constant a gives an indication of the initial porosity of the sample. Its higher value 130 
presumes the loose packing of the powder in the die before compression. Constant 1/b 131 
describes the pressure which is needed to reduce the powder bed volume by 50%. 132 
Higher coefficient 1/b implies higher cohesive energy of interaction, which shows up as 133 
a hindered particle rearrangement. 134 
The compressibility of the powder mixtures was investigated using the Walker (1923) 135 
equations (Eq. (6) and (7)): 136 
logP = -LV + C1 (6) 137 
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100V = -W logP + C (7) 138 
where P is the applied pressure in MPa, L is the pressing modulus which reflects the 139 
volume reduction at a given pressure, V is the relative volume, W is the Walker 140 
coefficient which gives information about the volume reduction corresponding to one-141 
decade change in the pressure, and C and C1 are constants. The relative volume is 142 
expressed by Eq. (8): 143 
V’/V0 (8) 144 
where V’ is the volume at the applied pressure and V0 is the initial volume of the powder 145 
bed in mm
3
. 146 
 147 
2.5. Post-compressional properties 148 
The mass, the thickness and the diameter of the prepared tablets were investigated with 149 
a Kraemer UTS-50 (Charles Ischi AG, Switzerland) tablet testing system right after the 150 
production and one week later in order to follow the changes in the geometrical 151 
parameters. 20 numbered tablets of each composition and compression force were 152 
characterized. The parameters above served to calculate the apparent density of the 153 
tablets. In addition to the apparent density, the study was completed with 154 
pycnometric density measurements allowing the determination of tablet porosity 155 
(see the applied method under Section 2.2.) 156 
The breaking strength of the tablets was studied with a Heberlein 2E/205 tablet hardness 157 
tester (Heberlein AG, Switzerland), measuring 10 tablets per composition per 158 
compression pressure. In addition, the tensile strength of the tablets was calculated 159 
using the following equation (Eq. (9)): 160 
 (9) 161 
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where  is the tensile strength in N, F is the breaking force in N, d is the diameter and h 162 
is the height of the tablet in mm. 163 
The texture of the prepared tablets was studied by taking Scanning Electron 164 
Micrographs of the surface, while their  breaking surface was examined with a 165 
Hitachi S4700 (Hitachi Ltd., Japan) scanning electron microscope. The tablets 166 
were stuck to a double-sided carbon adhesive tape and a conductive golden layer 167 
was deployed with the use a sputter apparatus (Polaron Ltd., UK). The 168 
measurements were performed at a magnification of 100-500, applying 10.0 kV of 169 
electron energy and 1.3-13 MPa of air pressure. 170 
The disintegration of the prepared tablets was investigated in distilled water with an 171 
Erweka ZT71 (Erweka GmbH, Germany) disintegration tester apparatus according to 172 
the criteria of the Eur. Pharmacopoeia [16].  173 
The drug release from the tablets was determined by an Erweka DT700 (Erweka 174 
GmbH, Germany) dissolution tester, using the USP II method [17]. The dissolution 175 
was tested at 37 °C, with pH 6.8 phosphate buffer as a dissolution medium. The 5-176 
ml aliquots were taken after 3, 5, 10, 15, 30, 60, 90, 120 minutes. The dissolved 177 
drug (µg/ml) was defined with a ThermoScientific GENESYS 10S UV-VIS 178 
spectrophotometer (Thermo Fisher Scientific Ltd., USA). 179 
 180 
3. Results and discussion 181 
3.1. Preformulational properties of the APIs and the API-TNT composites 182 
Within the preformulation studies, the determination of the flow properties, the Hausner 183 
Ratio and Compressibility Index values and the porosity of the samples was put into 184 
focus (Table 2.). The results showed uniformity in that the composites displayed 185 
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preferable flow properties compared to the pure APIs, irrespective of the incorporated 186 
API. 187 
The measurements revealed that the APIs have extremely poor flow properties. In 188 
contrast, favourable flowability was observed for the pure TNTs. As concerns the 189 
composites, the results are not consonant, the incorporation of DiltHCl and DicNa 190 
induced better (measurable) flow time, while the composite formation of ATN and HCT 191 
did not result in measurable flow time. This can be explained by the partially feasible 192 
incorporation of ATN and HCT into TNTs [18]. Therefore, as ATNTi and HCTTi 193 
products contain individual API crystals, the flowability improving effect of TNTs 194 
decreases or completely lags behind. 195 
The investigation of the particle rearrangement revealed an exponential-type 196 
rearrangement profile for all the samples (Fig.1). Regarding the calculated Hausner 197 
Ratio and Compressibility Index values, it is clearly visible that all the APIs reached an 198 
upper range of the USP scale of flowability [15] by the incorporation. The flowability of 199 
the composites varies between those of the component materials, which was expected 200 
based on the fact that the APIs are located not only in the inner parts of TNTs but on 201 
their surface as well [18]. The rate of the flowability improvement probably depends on 202 
the ratio of the surface coverage.  203 
The results of the pycnometric volume measurements confirmed that TNTs possess 204 
notably high pycnometric density and high porosity, which was expected due to the 205 
tubular structure and the great number of interparticular pores between the 206 
nanosized particles. Accordingly, the porosity of the composites is also greater than 207 
that of the pure APIs: this phenomenon was more expressed for DiltTi and DicTi, 208 
where the drug incorporation was complete, and less (or not) expressed for the 209 
partially incorporated ATNTi and HCTTi products. It is also notable that HCTTi, 210 
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where TNTs are attached to the surface of the HCT particles [18], exhibits slightly 211 
decreased porosity, which may be due to the decreasing number of interparticular 212 
pores. 213 
 214 
3.2. Compaction properties of the API and API-TNT containing powder mixtures 215 
The tablettability of the powder mixtures was thoroughly investigated by using an 216 
instrumented tablet press. 217 
Knowing the degree of volume reduction under pressure, the particle rearrangement 218 
of the powder mixtures was studied by using the Kawakita model. The results of the 219 
analysis were plotted; the graphs of the DiltHCl and DiltTi tablets are presented in Fig. 220 
2. The data fit the Kawakita model well with a R
2
 being at least 0.998. Constants a and 221 
1/b, which were obtained from the graphs, are displayed in Table 3. 222 
The values of constant a, which give information about the rearrangement of the 223 
powders, are very similar for all the samples. Although the preformulation studies 224 
presumed lower constant a values for the composite containing compositions, no 225 
remarkable differences could be noticed either between the four API tablet 226 
compositions or between the API and the related API-TNT tablet compositions. This 227 
result confirms the selection of an appropriate excipient profile for the tablets, resulting 228 
in powder mixtures with nearly the same flow properties. However, the fact that the 229 
compositions of the composites contain proportionally less excipient than those of the 230 
APIs implies the better flowability of the composites. 231 
The values of constant 1/b, which correlate with the cohesiveness, showed important 232 
differences between the API and API-TNT tablet compositions. Based on the several 233 
times higher 1/b values of the composite containing powders, it is clear that the 234 
composite content requires much higher energy to reduce the volume of the powder to 235 
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half of the original. The low1/b values can be explained by the fast collapse of the 236 
powders in the die, supporting our visual observations made during the preformulation 237 
studies. In contrast, powders with a high 1/b value exhibit continuous densification 238 
under increasing load. It can be seen that the relation between the value of constant a of 239 
the HCT and the HCTTi tablet compositions is different, and the HCTTi containing 240 
powder mixtures have a lower 1/b value than the HCT tablet composition. In order to 241 
make this exceptional behaviour clear, the structural properties of the HCTTi product 242 
have to be taken into consideration. As it was already mentioned, the incorporation of 243 
HCT into TNTs was not completely successful, resulting in a product which, besides the 244 
aggregated composites, contains HCT crystals covered with TNTs [18]. Owing to the 245 
surface coverage, the HCTTi product displays higher surface free energy than the pure 246 
HCT, therefore it shows superior adhesivity as well. For this reason, instead of 247 
improving compactibility, the HCTTi product generates an unfavourable particle 248 
rearrangement, showing an even worse compactibility profile than the pure API itself. 249 
The compressibility of the compositions was examined by applying the Walker model. 250 
From the plotted graphs (the graphs of DiltHCl and DiltTi tablets are shown in Fig. 3 251 
and 4) coefficients L and W were defined. The data are presented in Table 3. 252 
According to the results, coefficient L, also called pressing modulus, appeared to be 253 
lower for the composite containing compositions, reflecting their higher volume 254 
reduction at a given pressure compared to the tablet compositions containing pure API. 255 
This behaviour is supported by the preformulation studies, during which the composites 256 
revealed higher density than the APIs, and also by the fact that the composite formation 257 
results in smaller surface free energy [18]. The results of HCT and HCTTi tablet 258 
powder mixtures showed up again oppositely, thus the HCTTi containing composition 259 
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displayed a higher coefficient L value. This result is in perfect accordance with our 260 
conception described above. 261 
The obtained Walker coefficient values, which refer to the irreversible compressibility 262 
of the powders, correspond with the results discussed so far. The higher values of 263 
coefficient W shown by the composite containing compositions hint at plastic 264 
deformation and better tableting properties. In contrast, the smaller W values of tablet 265 
compositions containing pure API mark an extended densification maximum due to the 266 
high elastic recovery of the crystalline APIs. In this case again, the HCTTi composite 267 
containing powder mixture showed opposing behaviour as compared to the other API-268 
TNT tablet compositions, confirming the above-mentioned negative effect of the 269 
unsuccessful composite formation. 270 
Overall, it can be concluded that the incorporation of drugs into TNTs is advantageous 271 
and results in more ideal compaction behaviour. However, it is also important to remark 272 
that a partially successful composite formation may affect the compaction properties 273 
negatively, therefore the appropriate incorporation process plays a key role in this issue. 274 
 275 
3.3. Post-compressional properties of the API and API-TNT tablets 276 
The measurements of the geometric parameters allowed us to define the apparent 277 
density of the tablets right after the compression and one week later as well. The results 278 
are summarized in Table 4. 279 
Based on the data, it can be stated that the tablet density generally increases with the 280 
compression force. The only exception was shown by the ATN tablets, where the 281 
density measured right after compression decreased with the increase of the 282 
compression force. This phenomenon can be explained by the strong elasticity of ATN, 283 
which results in a rising elastic recovery with the increase of the compression force. 284 
 
 
13 
 
This conception is supported by the low value of coefficient W received from the 285 
Walker analysis (Table 3.). Nevertheless, the density values measured after one-286 
week storage show that the bonds in the ATN containing tablets undergo a 287 
considerably high consolidation during the first period of storage, which may also 288 
be observed in the case of other elastic systems [19]. It is also noteworthy that this 289 
phenomenon did not appear for the ATNTi tablets, which shows the positive effect of 290 
TNTs on elastic recovery. 291 
It can also be established from the data that the apparent density of the API-TNT tablets 292 
is higher than that of the API tablets for all the investigated compression forces. 293 
However, in the case of DicNa and DicTi tablets this statement is relevant only at higher 294 
compression forces, which supports the good rearrangement and compressibility 295 
properties of DicNa seen in Table 3. Nevertheless, it can be concluded that the presence 296 
of TNTs generally increases the apparent tablet density. 297 
It is also necessary to consider the post-compressional apparent density changes as they 298 
can provide further information about the processability of the APIs and their 299 
composites. The density of the DiltHCl tablets decreased in time at each compression 300 
force, while the density of the DicNa, ATN and HCT tablets increased during the one-301 
week storage. The decrease in density is probably due to the release of the stored stress 302 
by the tablet by increasing its volume, while the increase of tablet density is probably 303 
the result of the consolidating bonding forces. Regarding the API-TNT tablets, in the 304 
case of DiltTi and DicTi the density did not change at lower compression forces and 305 
only barely decreased beyond 10.0kN in time. These results support the plastic 306 
deformation of these composite containing compositions inducing stable tablet density 307 
at low compression forces and only slight changes in density at high compression 308 
pressure. On the other hand, the apparent density of the ATNTi and HCTTi tablets was 309 
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noticed to increase during the one-week storage at all compression forces. These results 310 
showing similarity to those of the ATN and HCT tablets certainly originate in the 311 
incomplete incorporation of these materials into TNTs. Furthermore, in the case of the 312 
HCTTi tablets it was also predictable based on the compaction studies. 313 
As regards the true density and the porosity of the tablets (Table 5.), those 314 
containing composites showed higher true density than API tablets, which is in 315 
accordance with the presented apparent densities as well as with the expectations 316 
built on the powder porosities shown in Table 2. The porosity of the tablets, which 317 
constantly decreased with the increase of the compression pressure, exhibits 318 
considerable differences with regard to the compressibility and the texture of the 319 
compositions. According to the preformulation results, all the composites have 320 
higher porosity than the pure APIs, due to the tubular structure of TNTs. This 321 
difference is clearly visible also for tablets prepared from composites which exhibit 322 
poorer compressibility (DicTi and ATNTi), while tablets prepared from DiltTi, 323 
which showed superior compressibility, have lower porosity than the 324 
corresponding DiltHCl tablets at all compression forces. A slight decrease of 325 
porosity may also be observed for the HCTTi tablets, but this can be due to the 326 
unique structure of the composite and not to the good compressibility of the 327 
composition.  328 
The forces required to break the tablets and the calculated tensile strength values are 329 
displayed in Table 6. 330 
As expected, the breaking strength increases with the compression force in all the cases. 331 
Based on the results, it is outstanding that the breaking strength of the API-TNT tablets 332 
is much superior to that of the API tablets at all compression forces. Moreover, in 333 
consonance with the results of the compaction measurements, the API-TNT tablets 334 
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display a greater increase in breaking strength between 5.0 and 15.0 kN compression 335 
force than the API tablets. According to the data, the less influence of the incorporation 336 
on the breaking strength was observed for DicNa, where a difference of 3.0 N could 337 
only be detected in the breaking strength of DicNa and DicTi tablets at 5.0 kN 338 
compression force. Although this difference slightly increased with the compression 339 
force, it was not remarkable at 15.0 kN either. This observation is in agreement with the 340 
results of the apparent density measurements. Comparing the four APIs, HCT (and 341 
therefore HCTTi) tablets showed the biggest breaking strengths at each compression 342 
force. In accordance with the high apparent density values displayed in Table 4., these 343 
results prove their greater hardness compared to the other samples.  344 
The disintegration time of the API and API-TNT tablets was investigated in order to 345 
reveal the effect of the composite formation on the disintegration and therefore its 346 
impact on drug dissolution. The results of the measurements are shown in Table 6. 347 
As expected, the disintegration time rose with the compression pressure in all the cases. 348 
When comparing the API and API-TNT tablets, it can be stated that the disintegration 349 
of the composite containing tablets is slower at each investigated compression pressure. 350 
The superior disintegration times of the API-TNT tablets refer to their greater hardness, 351 
confirming the findings of the above post-compression studies.  352 
The most considerable effect of the incorporation on the disintegration time was seen 353 
for the ATN tablets as a result of the important difference in strength observed between 354 
the ATN and ATNTi tablets. It is noteworthy that the partial incorporation of HCT is 355 
clearly reflected in the results: the HCT and HCTTi tablets show similar disintegration 356 
time values. It is also interesting to note that despite their high hardness and apparent 357 
density, the HCT and HCTTi tablets disintegrate very quickly and, in contrast with the 358 
other compositions, their disintegration is less dependent on the compression pressure. 359 
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The scanning electron micrographs of the tablets (Fig. 5.) support the results of the 360 
compressibility studies, according to which the HCT and HCTTi tablets go through a 361 
considerably higher densification already at lower compression forces, resulting in 362 
smaller porosity. The SEM pictures also reveal that the irregular densification may be 363 
due to the fragmentation of the HCT particles, which may also be an explanation for the 364 
fast disintegration process. The water penetrating into the microfractures (marked with 365 
white arrows) of the HCT particles disrupts the fractures and the released energy 366 
enhances the disintegration process. 367 
The results of the dissolution tests are presented in Fig. 6. In general, slower drug 368 
release may be observed from the API-TNT tablets than from the related API 369 
tablets in all the cases. This may be explained by the slower disintegration, due to 370 
the higher breaking strength and density of these tablets, independently from their 371 
porosity. This may support the conclusion that the observed porosity differences 372 
between the APIs and the composites are due to the tubular structure of TNTs and 373 
not to the looser tablet skeleton. It is important to note that the occurrence of 374 
strong interactions may also change the kinetics of the drug release, as observed in 375 
the case of DicNa, where the first order drug dissolution from the DicNa tablets 376 
changed to prolonged dissolution based on Korsmeyer-Peppas kinetics from the 377 
DicTi tablets. In accordance with the expectations, the speed of dissolution 378 
decreased with the increase of the compression force in the case of the API and 379 
API-TNT tablets as well. However, it could be seen that this slowing down of 380 
dissolution was more intense for the API-TNT tablets, confirming the especially 381 
good compressibility and compactibility of the composites. 382 
 383 
4. Conclusion 384 
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The present study aimed to determine the effect of 1:1 ratio API-TNT composite 385 
formation on the tablettability of the incorporated API. Four different composite 386 
products were used to obtain reliable results. 387 
The preformulation measurements revealed that the composite formation with TNTs 388 
highly improved the extremely poor flowability of the APIs. This positive effect of 389 
TNTs on powder rheology was proved for all the investigated APIs, indicating 390 
promising opportunities for developing drug processability with the use of TNTs. 391 
However, the rate of flowability improvement was seen to be dependent on the 392 
efficiency of the incorporation process; ATNTi and HCTTi showed slighter flowability 393 
improvement. 394 
When comparing the compaction properties of the API and API-TNT tablets, it was 395 
seen that the composite formation resulted in better compactibility, showing higher 396 
volume reduction at a given compression pressure. Furthermore, drug incorporation into 397 
TNTs hindered the elastic recovery of the APIs and led to plastic deformation. These 398 
results confirmed the great advantage of composite formation for manufacturing tablets 399 
with direct compression. On the other hand, the measurements also revealed that 400 
inappropriate incorporation may also affect the compaction behaviour of the API 401 
negatively, as observed for HCT. Accordingly, the successfulness of the incorporation 402 
is considered to be the key factor of the tablettability improving effect of TNTs. 403 
In accordance with the more ideal compaction behaviour, the API-TNT tablets showed 404 
better post-compressional properties than the tablets containing pure APIs, displaying 405 
higher apparent density, superior breaking strength and slower disintegration at all the 406 
applied compression forces. The greater strength of the API-TNT tablets compared to 407 
that of the pure APIs was observed for all the APIs without reference to the efficacy of 408 
the incorporation. 409 
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Overall, the present work revealed that the appropriate incorporation of APIs into TNTs 410 
highly improves their tablettability and results in tablets with favourable mechanical 411 
properties. Accordingly, it can be concluded that hydrothermally synthesized TNTs can 412 
advantageously be used as drug carriers in the manufacturing of tablets with direct 413 
compression. 414 
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Figure captions 492 
Figure 1: Particle rearrangement profile of TNTs, APIs and API-TNT composites 493 
Figure 2: Kawakita-Lüdde plot of DiltHCl and DiltTi containing powder mixtures 494 
Figure 3: Walker W plot of DiltHCl and DiltTi containing powder mixtures 495 
Figure 4: Walker L plot of DiltHCl and DiltTi containing powder mixtures 496 
Figure5: SEM micrographs of tablets (DicTi 5kN tablet surface (a) and breaking 497 
surface (b); DicTi 15kN tablet surface (c), breaking surface (d); HCTTi 5 kN tablet 498 
surface (e), breaking surface (f); HCTTi 15 kN tablet surface (g), breaking surface 499 
(h)) 500 
Figure 6: Drug dissolution from API and API-TNT tablets compressed with 5.0, 501 
7.5, 10.0, 12.5 and 15.0 kN in pH 6.8 phosphate buffer 502 
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Table 1. Composition of API and API-TNT tablets 
Materials API tablets API-TNT tablets 
API 16.7%  - 
API-TNT  - 33.3% 
Avicel PH 112 50.0% 39.5% 
Tablettose 29.3% 23.2% 
Talc 3.0% 3.0% 
Mg-stearate 1.0% 1.0% 
 
  
Table(s)
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Table 2. Preformulation results of the APIs and the API-TNT composites 
Material 
Flow 
time 
(sec) 
Angle of 
repose (°) 
Bulk 
density 
(g/cm^3) 
Tapped 
density 
(g/cm^3) 
Pycnometric 
density 
(g/cm^3) 
Porosity 
(%) 
Hausner 
Ratio 
Compressibility 
Index (%) 
Flowability 
(USP scale) 
TNT 14.3 25.5 0.65 0.76 3.02 78.51 1.17 14.47 good 
DiltHCl   n.m. - 0.45 0.59 1.30 65.34 1.31 23.73 passable 
DiltTi   16.5 28.2 0.51 0.64 1.78 71.39 1.25 20.31 fair 
DicNa   n.m. - 0.48 0.73 1.50 68.01 1.52 34.25 very poor 
DicTi   6.3 28.4 0.55 0.68 1.97 72.05 1.24 19.12 fair 
ATN  n.m. - 0.3 0.48 1.21 75.16 1.6 37.5 very very poor 
ATNTi   n.m. - 0.38 0.49 1.64 76.81 1.29 22.45 passable 
HCT n.m. - 0.46 0.76 1.69 72.72 1.65 39.47 very very poor 
HCTTi n.m. - 0.61 0.76 2.17 71.94 1.25 19.74 fair 
n.m.=not measurable 
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Table 3. Parameters calculated from Kawakita and Walker plots 
Tablet a 1/b L W 
DiltHCl 0.68 8.03 7.9 11.59 
DiltTi 0.62 18.63 5.93 16.49 
DicNa 0.67 6.38 9.85 8.72 
DicTi 0.68 13.53 6.64 14.73 
ATN 0.64 5.94 13.56 4.04 
ATNTi 0.65 17.61 8.47 9.43 
HCT 0.61 14.32 12.89 7.01 
HCTTi 0.68 6.04 17.76 2.49 
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Table 4. Apparent density of the API and API-TNT tablets determined right after 
the preparation and one week later 
  API Composite 
Pressing 
force 
(kN) 
0 h 168 h 0 h 168 h 
Apparent 
density 
SD 
Apparent 
density 
SD 
Apparent 
density 
SD 
Apparent 
density 
SD 
 DiltHCl DiltTi 
5.0 1.09 0.01 1.06 0.01 1.23 0.01 1.23 0.00 
7.5 1.18 0.01 1.15 0.01 1.30 0.00 1.30 0.00 
10.0 1.25 0.01 1.23 0.01 1.35 0.02 1.35 0.01 
12.5 1.29 0.01 1.27 0.01 1.40 0.01 1.39 0.00 
15.0 1.30 0.07 1.28 0.08 1.42 0.00 1.40 0.00 
  DicNa DicTi 
5.0 1.16 0.01 1.16 0.01 1.16 0.00 1.16 0.01 
7.5 1.23 0.02 1.26 0.02 1.23 0.01 1.23 0.02 
10.0 1.27 0.01 1.32 0.02 1.32 0.00 1.32 0.00 
12.5 1.30 0.01 1.35 0.02 1.36 0.01 1.35 0.02 
15.0 1.34 0.01 1.40 0.01 1.42 0.00 1.40 0.04 
  ATN ATNTi 
5.0 1.11 0.01 1.25 0.01 1.15 0.01 1.31 0.01 
7.5 1.04 0.01 1.28 0.01 1.20 0.01 1.37 0.00 
10.0 1.01 0.01 1.28 0.01 1.23 0.01 1.40 0.01 
12.5 0.93 0.00 1.30 0.01 1.24 0.01 1.42 0.01 
15.0 0.92 0.01 1.32 0.01 1.25 0.02 1.43 0.01 
  HCT HCTTI 
5.0 1.03 0.01 1.28 0.01 1.17 0.00 1.39 0.01 
7.5 1.07 0.01 1.33 0.01 1.20 0.01 1.42 0.00 
10.0 1.09 0.03 1.39 0.01 1.26 0.00 1.48 0.01 
12.5 1.11 0.00 1.40 0.00 1.31 0.00 1.48 0.01 
15.0 1.12 0.00 1.41 0.00 1.37 0.00 1.52 0.00 
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Table 5. True density and porosity of the API and API-TNT tablets 
Pressing 
force 
(kN) 
True 
density 
(g/cm
3
) 
SD 
Porosity 
(%) 
SD 
True 
density 
(g/cm
3
) 
SD 
Porosity 
(%) 
SD 
DiltHCl DiltTi 
5.0 1.0517 0.0098 29.41 0.45 1.6336 0.0080 24.70 0.36 
7.5 1.0517 0.0098 23.42 0.49 1.6336 0.0080 20.42 0.38 
10.0 1.0517 0.0098 18.09 0.53 1.6336 0.0080 17.35 0.40 
12.5 1.0517 0.0098 15.43 0.54 1.6336 0.0080 14.91 0.41 
15.0 1.0517 0.0098 14.76 0.55 1.6336 0.0080 14.29 0.41 
 DicNa DicTi 
5.0 1.5426 0.0065 24.80 0.31 1.6685 0.0151 30.47 0.62 
7.5 1.5426 0.0065 18.31 0.34 1.6685 0.0151 26.27 0.66 
10.0 1.5426 0.0065 14.42 0.36 1.6685 0.0151 20.88 0.71 
12.5 1.5426 0.0065 12.48 0.37 1.6685 0.0151 19.08 0.73 
15.0 1.5426 0.0065 9.243 0.38 1.6685 0.0151 16.08 0.75 
 
ATN ATNTi 
5.0 1.4721 0.0045 15.08 0.26 1.5953 0.0043 17.88 0.21 
7.5 1.4721 0.0045 13.04 0.26 1.5953 0.0043 14.11 0.22 
10.0 1.4721 0.0045 13.04 0.26 1.5953 0.0043 12.23 0.23 
12.5 1.4721 0.0045 11.68 0.27 1.5953 0.0043 10.98 0.23 
15.0 1.4721 0.0045 10.33 0.27 1.5953 0.0043 10.35 0.23 
 HCT HCTTi 
5.0 1.5918 0.0038 19.55 1.87 1.6909 0.0289 17.77 1.39 
7.5 1.5918 0.0038 16.40 1.94 1.6909 0.0289 16.00 1.42 
10.0 1.5918 0.0038 12.63 2.03 1.6909 0.0289 12.45 1.49 
12.5 1.5918 0.0038 12.01 2.05 1.6909 0.0289 12.45 1.49 
15.0 1.5918 0.0038 11.38 2.06 1.6909 0.0289 10.08 1.53 
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Table 6. Breaking and tensile strength of the API and API-TNT tablets 
Pressing 
force 
(kN) 
Breaking 
strength (N) 
SD 
Tensile 
strength (N) 
SD 
Breaking 
strength (N) 
SD 
Tensile 
strength (N) 
SD 
DiltHCl DiltTi 
5.0 24.9 1.1 0.47 0.02 69.0 1.79 1.42 0.04 
7.5 53.0 3.63 1.09 0.06 96.0 2.37 2.08 0.05 
10.0 66.2 4.47 1.60 3.68 122.0 4.86 2.83 0.09 
12.5 104.0 4.53 2.35 0.08 142.0 2.66 3.37 0.06 
15.0 124.0 3.19 2.83 0.10 156.0 2.86 3.79 0.05 
 DicNa DicTi 
5.0 42.9 2.64 0.85 0.05 46.0 3.04 0.93 0.05 
7.5 58.1 3.68 1.21 0.08 66.0 2.80 1.44 0.05 
10.0 81.2 4.58 1.74 0.07 99.0 3.63 2.27 0.08 
12.5 98.1 3.91 2.17 0.08 120.0 3.30 2.83 0.07 
15.0 125.0 3.00 2.73 0.07 153.0 3.05 3.80 0.06 
 
ATN ATNTi 
5.0 79.5 2.90 1.68 0.06 102.0 4.56 1.99 0.09 
7.5 82.4 2.08 1.75 0.04 121.0 1.97 2.48 0.05 
10.0 89.6 1.60 1.99 0.04 138.0 2.77 2.88 0.05 
12.5 101.0 4.27 2.02 0.09 141.0 2.19 3.00 0.05 
15.0 102.0 3.08 2.13 0.08 149.0 4.34 3.24 0.09 
 HCT HCTTi 
5.0 87.0 4.20 1.63 0.08 127.0 3.16 2.65 0.07 
7.5 112.0 3.84 2.18 0.07 148.0. 3.64 3.14 0.07 
10.0 149.0 4.81 2.92 0.20 190.0 3.10 4.13 0.07 
12.5 153.0 3.40 3.10 0.06 191.0 3.50 4.32 0.08 
15.0 160.0 4.00 3.22 0.10 222.0 2.72 5.14 0.06 
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Table 7. Disintegration time of the API and API-TNT tablets 
Compressing 
force (kN) 
Disintegration 
time(min) 
SD 
Disintegration 
time(min) 
SD 
 DiltHCl DiltTi 
5.0 0.16 0.02 0.52 0.03 
7.5 0.41 0.17 2.44 0.29 
10.0 8.28 0.68 9.54 0.49 
12.5 11.07 1.34 15.49 0.27 
15.0 18.13 0.52 18.46 0.52 
 
DicNa DicTi 
5.0 0.20 0.01 1.34 0.09 
7.5 0.41 0.05 2.13 0.05 
10.0 1.05 0.13 3.21 0.41 
12.5 1.58 0.19 4.26 0.65 
15.0 4.23 0.05 5.27 0.37 
 
ATN ATNTi 
5.0 1.05 0.09 4.95 0.35 
7.5 1.56 0.28 9.56 0.17 
10.0 3.33 0.33 13.40 0.37 
12.5 5.40 0.48 15.30 0.46 
15.0 6.26 0.18 18.62 0.43 
 
HCT HCTTi 
5.0 0.12 0.02 0.31 0.06 
7.5 0.18 0.03 0.48 0.16 
10.0 0.23 0.06 1.18 0.13 
12.5 0.23 0.06 1.43 0.07 
15.0 0.28 0.03 3.19 0.30 
 
 
 
 
